RxDoctor Payments Data

John Eagan, MD

Cardiovascular Disease · Birmingham, ALNPI 1881683365

Payments from drug & device makers

$779in general payments, 2019–2025

Across 13 payments — averaging $59.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Siemens Medical Solutions USA, Inc.$169
  • Biosense Webster, Inc.$147
  • Inari Medical, Inc.$144
  • Abbott$120
  • Philips North America LLC$79
  • Medtronic$39
  • plus $81 from 4 others

What the payments were for

  • Food & beverage$779100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$779 in reported general payments places this provider in the 20th percentile of 292 cardiovascular disease providers in Alabama.

See all cardiovascular disease providers in Alabama

Medicare billing

Part B allowed, 2024
$338,661
Medicare patients
1,475
Services billed
5,072

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban919$816,973
EntrestoSacubitril/Valsartan261$250,511
JardianceEmpagliflozin199$190,401
XareltoRivaroxaban128$141,168
Repatha SureclickEvolocumab109$76,425
Atorvastatin Calcium1,129$18,139
Ranolazine ErRanolazine155$15,659
Metoprolol Succinate859$14,833
LivaloPitavastatin Calcium14$11,146
Rosuvastatin Calcium499$10,102
Losartan Potassium571$9,637
Amlodipine Besylate853$7,742
Ezetimibe261$7,727
Carvedilol536$5,498
ClopidogrelClopidogrel Bisulfate380$5,042

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$22$250,511261 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 292 cardiovascular disease providers in Alabama.

Other cardiovascular disease in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →